Why Revolution Medicines (RVMD) Stock Is Up Today

Revolution Medicines (RVMD) is up 5.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor optimism around daraxonrasib after the company said the U.S. FDA accepted its new drug application for previously treated metastatic pancreatic cancer, a major regulatory step for its lead asset. The move also appears to be supported by recent bullish sell-side commentary and pipeline updates, so today’s gain may reflect momentum rather than a single fresh headline. ([ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/))

Details:

In July 2026, the company said the FDA accepted daraxonrasib for review in previously treated metastatic pancreatic ductal adenocarcinoma, with the filing backed by Phase 3 data that met primary and key secondary endpoints. ([ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/))

The same update highlighted improved survival, progression-free survival, and patient-reported quality-of-life measures versus chemotherapy, which strengthened the commercial case for the drug candidate. ([ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/))

Management has also kept advancing the broader RAS-targeted pipeline, including additional late-stage studies in pancreatic cancer and other solid tumors, helping sustain enthusiasm around the long-term story. ([ir.revmed.com](https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-begins-treating-patients-rasolute-305-phase/?utm_source=openai))

Recent analyst commentary has remained constructive, with multiple firms lifting price targets after new clinical updates, which could be adding support to the shares. ([investing.com](https://www.investing.com/news/analyst-ratings/truist-reiterates-buy-on-revolution-stock-keeps-210-target-93CH-4786330))

Sources:

Revolution Medicines, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RVMD Insider Trading Activity

$RVMD insiders have traded $RVMD stock on the open market 56 times in the past 6 months. Of those trades, 0 have been purchases and 56 have been sales.

Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

MARK A GOLDSMITH (See Remarks) has made 0 purchases and 16 sales selling 178,891 shares for an estimated $24,499,564.
MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 10 sales selling 104,583 shares for an estimated $16,350,041.
ANTHONY MANCINI (See Remarks) has made 0 purchases and 12 sales selling 48,306 shares for an estimated $5,193,050.
STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 2 sales selling 8,477 shares for an estimated $1,079,762.
SUSHIL PATEL has made 0 purchases and 9 sales selling 5,580 shares for an estimated $1,048,967.
JACK ANDERS (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,475 shares for an estimated $698,826.
JEFF CISLINI (General Counsel) has made 0 purchases and 3 sales selling 5,115 shares for an estimated $628,638.
LIN WEI (Chief Medical Officer) sold 2,073 shares for an estimated $206,222
XIAOLIN WANG (See Remarks) sold 2,010 shares for an estimated $199,955

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$RVMD Hedge Fund Activity

We have seen 473 institutional investors add shares of $RVMD stock to their portfolio, and 226 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DARWIN GLOBAL MANAGEMENT, LTD. added 8,418,804 shares (+380.8%) to their portfolio in Q2 2026, for an estimated $1,576,673,613
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,878,385 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $913,623,942
CAPITAL WORLD INVESTORS added 4,008,244 shares (+inf%) to their portfolio in Q2 2026, for an estimated $750,663,936
FMR LLC added 3,736,108 shares (+44.1%) to their portfolio in Q2 2026, for an estimated $699,698,306
JPMORGAN CHASE & CO added 3,298,066 shares (+inf%) to their portfolio in Q2 2026, for an estimated $617,661,800
BLACKROCK, INC. added 2,483,084 shares (+22.1%) to their portfolio in Q2 2026, for an estimated $465,031,971
WELLINGTON MANAGEMENT GROUP LLP removed 2,184,404 shares (-36.2%) from their portfolio in Q2 2026, for an estimated $409,095,181

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RVMD Price Targets

Multiple analysts have issued price targets for $RVMD recently. We have seen 15 analysts offer price targets for $RVMD in the last 6 months, with a median target of $195.0.

Here are some recent targets:

Michael Schmidt from Guggenheim set a target price of $235.0 on 07/09/2026
Joseph Catanzaro from Mizuho set a target price of $215.0 on 07/06/2026
Robert Burns from HC Wainwright & Co. set a target price of $195.0 on 07/06/2026
Robert Driscoll from Wedbush set a target price of $181.0 on 07/02/2026
Gregory Renza from Truist Securities set a target price of $210.0 on 06/30/2026
Ami Fadia from Needham set a target price of $235.0 on 06/29/2026
Cory Kasimov from Evercore ISI Group set a target price of $220.0 on 06/10/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.